New Drug Could Lower Risk of Alzheimer's Disease, Study Finds
- Researchers recently tested the drug SW033291 on mice to assess its effects on Alzheimer's disease symptoms.
- Researchers used the drug SW033291 to inhibit the enzyme 15-PGDH, whose activity increases within the blood-brain barrier as Alzheimer's disease develops.
- The drug helped mice retain memory and brain function, showed protection against brain damage, and was effective even a day after brain injury.
- Published on May 21, the study highlights SW033291’s potential to preserve cognitive skills and possibly offer a safer treatment or prevention method for Alzheimer's disease.
- Further research and human clinical trials are necessary before SW033291 can be approved for Alzheimer's treatment or prevention.
27 Articles
27 Articles
USC Scientists Unveil 5-in-1 Blood Test for Early Alzheimer’s Detection
In a proof-of-concept study, the test successfully identified five critical biomarkers associated with Alzheimer’s disease, exceeding the capabilities of currently available commercial blood tests. Researchers at the Keck School of Medicine of USC have created a new blood test that could make it easier to detect Alzheimer’s disease early. This innovative tool, called the Penta-Plex [...]
A common sleep aid blocks neurodegeneration in mice
A common sleep aid restores healthier sleep patterns and protects mice from the brain damage seen in neurodegenerative disorders, such as Alzheimer's disease, according to new research from Washington University School of Medicine in St. Louis. The drug, lemborexant, prevents the harmful buildup of an abnormal form of a protein called tau in the brain, reducing the inflammatory brain damage tau is known to cause in Alzheimer's.
Blood test pinpoints early Alzheimer’s risk with high accuracy
Researchers evaluated a fully automated plasma biomarker panel to detect early amyloid-β accumulation in cognitively unimpaired adults at risk for Alzheimer’s disease. Plasma p-tau217/Aβ42 emerged as the most robust and accurate blood-based marker for identifying preclinical amyloid pathology.
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium